823221-93-8 Usage
General Description
5-Bromo-2-chloro-4-(trifluoromethyl)pyridine is a chemical compound with the molecular formula C6H3BrClF3N. It is a pyridine derivative with a bromine and a chlorine atom attached to the second and fourth positions of the pyridine ring, respectively, and a trifluoromethyl group attached to the fourth position. This chemical compound is used in the pharmaceutical and agrochemical industries as a building block for the synthesis of various biologically active compounds, such as pharmaceutical drugs and agricultural pesticides. It is also utilized as a reagent in organic synthesis and as an intermediate in the manufacturing of specialty chemicals. Due to its unique structure and properties, 5-Bromo-2-chloro-4-(trifluoromethyl)pyridine has potential applications in various fields, including medicinal chemistry, materials science, and chemical research.
Check Digit Verification of cas no
The CAS Registry Mumber 823221-93-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,2,3,2,2 and 1 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 823221-93:
(8*8)+(7*2)+(6*3)+(5*2)+(4*2)+(3*1)+(2*9)+(1*3)=138
138 % 10 = 8
So 823221-93-8 is a valid CAS Registry Number.
InChI:InChI=1/C6H2BrClF3N/c7-4-2-12-5(8)1-3(4)6(9,10)11/h1-2H
823221-93-8Relevant articles and documents
INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
-
Paragraph 00162, (2019/04/10)
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
-
Paragraph 00320; 00322-00323, (2017/09/15)
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
